<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940203-0-00045</title>
	</head>
	<body>
		<main>
			<p><!-- PJG ITAG l=10 g=1 f=2 --> EFFECTIVE DATE: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  February 3, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> <!-- PJG STAG 4700 -->  <!-- PJG ITAG l=94 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=50 g=1 f=1 -->   <USDEPT>DEPARTMENT OF HEALTH AND HUMAN SERVICES</USDEPT>  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 -->  <USBUREAU>Food and Drug Administration</USBUREAU> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 -->  <CFRNO>21 CFR Part 524</CFRNO> <!-- PJG 0012 frnewline --> Ophthalmic and Topical Dosage Form New Animal Drugs; Neomycin, Penicillin, Polymyxin, Hydrocortisone Topical Suspension <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Food and Drug Administration, HHS. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Final rule. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect codification of a previously approved new animal drug application (NADA) held by Upjohn Co. The NADA provides for the safe use of Forte-Topical <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=6 f=2 --> &reg; <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Suspension (neomycin, penicillin, polymyxin, hydrocortisone suspension) as a topical antibacterial and anti-inflammatory agent in dogs. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </SUMMARY> <DATE> <!-- PJG ITAG l=10 g=1 f=2 --> EFFECTIVE DATE: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  February 3, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </DATE> <FURTHER> <!-- PJG ITAG l=10 g=1 f=2 --> FOR FURTHER INFORMATION CONTACT: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Dianne T. McRae, Center for Veterinary Medicine (HFV&hyph;102), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301&hyph;594&hyph;1623. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </FURTHER> <SUPPLEM> <!-- PJG ITAG l=10 g=1 f=2 --> SUPPLEMENTARY INFORMATION: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Upjohn Co., Kalamazoo, MI 49001, is sponsor of NADA 65&hyph;119 which provides for the safe use of Forte-Topical <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=6 f=2 --> &reg; <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Suspension. Each milliliter contains 25 milligrams (mg) of neomycin sulfate, 10,000 international units (IU's) of penicillin G procaine, 5,000 IU's of polymyxin B sulfate, 2 mg of hydrocortisone acetate, and 1.25 mg of hydrocortisone sodium succinate for the topical treatment of dogs for summer eczema, atopic dermatitis, interdigital eczema, and otitis externa caused by bacteria susceptible to neomycin, penicillin, and polymyxin B. The product was originally approved on September 15, 1959. Accordingly, the regulations in 21 CFR 524.1484h are amended to reflect approval of the NADA. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> In accordance with the freedom of information provisions of 21 CFR part 20 and 21 CFR 514.11(e)(2)(i) for NADA's approved prior to July 1, 1975, a summary of safety and effectiveness data and information submitted to support approval of this application is not required. <!-- PJG 0012 frnewline --> FDA has determined under 21 CFR 25.24(d)(1)(i) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> List of Subjects in 21 CFR Part 524  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Animal drugs. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 524 is amended as follows: <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 --> PART 524_OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 1. The authority citation for 21 CFR part 524 continues to read as follows: <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=4 --> Authority: <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 -->  Sec. 512 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b). <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> 2. New &sect;524.1484h is added to read as follows: <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;524.1484h  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Neomycin, penicillin, polymyxin, hydrocortisone suspension. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (a)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Specifications <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Each milliliter of suspension contains 25 milligrams of neomycin sulfate equivalent to 17.5 milligrams of neomycin, 10,000 international units of penicillin G procaine, 5,000 international units of polymyxin B sulfate, 2 milligrams of hydrocortisone acetate, and 1.25 milligrams of hydrocortisone sodium succinate. <!-- PJG 0012 frnewline --> (b)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Sponsor <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . See 000009 in &sect;510.600(c) of this chapter. <!-- PJG 0012 frnewline --> (c)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Special considerations <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The labeling shall state: This medication contains penicillin. Allergic reactions in humans are known to occur from topical exposure to penicillin.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (d)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Conditions of use_dogs_(1) Amount <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Rub a small amount into the involved area 1 to 3 times a day. After definite improvement, it may be applied once a day or every other day.  <!-- PJG 0012 frnewline --> (2)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Indications for use <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Treatment of summer eczema, atopic dermatitis, interdigital eczema, and otitis externa caused by bacteria susceptible to neomycin, penicillin, and polymyxin B. <!-- PJG 0012 frnewline --> (3)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Limitations <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . For use in dogs only. Shake drug thoroughly and clean lesion before using. If redness, irritation, or swelling persists or increases, discontinue use and reevaluate diagnosis. Federal law restricts this drug to use by or on the order of a licensed veterinarian. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: January 27, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUPPLEM> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 -->  Robert C. Livingston, <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 -->  Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;2400 Filed 2&hyph;2&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4160&hyph;01&hyph;F <!-- PJG /ITAG --> </BILLING>  <!-- PJG /STAG --></p>
		</main>
</body></html>
            